TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17637268

Group type: EXPERIMENTAL
Intervention: ADV + LAM (10 mg/d ADV and 100 mg/d LAM for 12 weeks, followed by 10 mg/d ADV for 36 weeks)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo + LAM (placebo and 100 mg/d LAM for 12 weeks, followed by 10 mg/d ADV for 36 weeks)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: ADV + LAM
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo + LAM
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Both treatment arms after 36 weeks of therapy
Number of subjects: 226
Study: 15275698

Group type: EXPERIMENTAL
Intervention: Melatonin (MLT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 12680528

Group type: EXPERIMENTAL
Intervention: Solid meal (175 kcal)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Solid meal (375 kcal)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Semisolid meal
Number of subjects: 18

Group type: COMPARATOR
Intervention: Liquid meal
Number of subjects: 18
Study: 9830787

Group type: EXPERIMENTAL
Intervention: High daily dose of angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low daily dose of angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study: 7793222

Group type: EXPERIMENTAL
Intervention: heterologous erythrocyte concentrate (group I)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: intra- and postoperative autotransfusion of blood salvaged with cellsaver technique (group II)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: predonated autologous erythrocyte concentrates together with salvaged blood (group III)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sonoclot coagulation analyses
Number of subjects: 45
Study: 2292532

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 200 mg bd
Number of subjects: 251

Group type: COMPARATOR
Intervention: Co-amoxiclav 500 mg/125 mg tds
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil
Number of subjects: 251
Study: 6898629

Group type: EXPERIMENTAL
Intervention: Self Instructional Unit (SIU) on nursing care plans
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Question Text Type (QTT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Information Text Type (ITT)
Number of subjects: 48
Study: 31777204

Group type: EXPERIMENTAL
Intervention: Individualized feedback
Number of subjects: 1089

Group type: EXPERIMENTAL
Intervention: Standardized feedback
Number of subjects: 1089
Study: 28913671

Group type: EXPERIMENTAL
Intervention: Educational program based on PRECEDE model
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 300
Study: 27353505

Group type: EXPERIMENTAL
Intervention: blisibimod (200 mg QW)
Number of subjects: 547

Group type: COMPARATOR
Intervention: blisibimod (placebo)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: blisibimod
Number of subjects: 547
Study: 25944629

Group type: EXPERIMENTAL
Intervention: Polypill strategy
Number of subjects: 94
Study: 23384944

Group type: EXPERIMENTAL
Intervention: Cognitive function assessed using Hodkinson Abbreviated Mental Test (AMT) at baseline and 18 months follow-up.
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: NYHA class IV patients compared to NYHA II patients.
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Presence of SCI related to mortality.
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Changes in HF severity.
Number of subjects: 611
Study: 21459499

Group type: EXPERIMENTAL
Intervention: Birth ball exercise programme (26-page booklet and 19-minute videotape, practiced at home for at least 20 minutes three times a week for 6-8 weeks)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Standard nursing and midwifery care (Control group)
Number of subjects: 188
Study: 19892282

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (laser probe positioned without actual laser intervention)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no laser intervention)
Number of subjects: 60
Study: 17044770

Group type: EXPERIMENTAL
Intervention: Tomato drink (250 ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 20
Study: 12772138

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine 1:200,000 and bicarbonate
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (lidocaine group)
Number of subjects: 42
Study: 10702463

Group type: EXPERIMENTAL
Intervention: RAB-RAB (rabeprazole-rabeprazole)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PLA-RAN (placebo-ranitidine)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: LAN-LAN (lansoprazole-lansoprazole)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PLA-RAB (placebo-rabeprazole)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: RAB-PLA (rabeprazole-placebo)
Number of subjects: 180

Group type: COMPARATOR
Intervention: PLA-PLA (placebo-placebo)
Number of subjects: 180
Study: 2060566

Group type: EXPERIMENTAL
Intervention: Doxorubicin (50 mg/m2 as an iv bolus) administered at 21.00 h
Number of subjects: 18

Group type: COMPARATOR
Intervention: Doxorubicin (50 mg/m2 as an iv bolus) administered at 09.00 h
Number of subjects: 18
Study: 6340496

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (2 mg/kg bolus, then 0.5 mg/kg per hour for 24 hours)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 20
Study: 30876402

Group type: EXPERIMENTAL
Intervention: Female interviewers
Number of subjects: 965

Group type: COMPARATOR
Intervention: Not accounting for interviewer identity in regressions
Number of subjects: 965
Study: 30124724

Group type: EXPERIMENTAL
Intervention: Halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion
Number of subjects: 418

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 418
Study: 26487000

Group type: EXPERIMENTAL
Intervention: Surgical resection (SR)
Number of subjects: 1009

Group type: COMPARATOR
Intervention: Transarterial chemoembolization (TACE)
Number of subjects: 1009
Study: 25127210

Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isotonic saline 0.9%
Number of subjects: 40
Study: 23118981

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 115

Group type: COMPARATOR
Intervention: Stretching exercise
Number of subjects: 115
Study: 20347511

Group type: EXPERIMENTAL
Intervention: Alendronate, 70 mg, administered weekly (n = 25)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo, matching (n = 25)
Number of subjects: 51
Study: 18585542

Group type: EXPERIMENTAL
Intervention: Olanzapine orally disintegrating tablet (OLZ‐ODT)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Risperidone oral solution (RIS‐OS)
Number of subjects: 87
Study: 16048422

Group type: EXPERIMENTAL
Intervention: Perturbation training
Number of subjects: 17

Group type: COMPARATOR
Intervention: Subjects without injuries (control group)
Number of subjects: 17
Study: 12453852

Group type: EXPERIMENTAL
Intervention: vinorelbine-cisplatin (NP; vinorelbine 30 mg/m(2) on days 1, 8 and 15 with cisplatin 80 mg/m(2) on day 1)
Number of subjects: 259

Group type: COMPARATOR
Intervention: vinorelbine-ifosfamide-cisplatin (NIP; vinorelbine 25 mg/m(2) on days 1 and 8, ifosfamide 3 g/m(2) on day 1 and cisplatin 75 mg/m(2) on day 1)
Number of subjects: 259
Study: 10325913

Group type: EXPERIMENTAL
Intervention: 100 micrograms/day budesonide
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 400 micrograms/day budesonide
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 1600 micrograms/day budesonide
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 8953661

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1710483

Group type: EXPERIMENTAL
Intervention: Intrapleural mitoxantrone
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (pleural tube alone with instillation of isotonic NaCl)
Number of subjects: 103
Study: 6725040

Group type: EXPERIMENTAL
Intervention: Radiosensitizing drug in radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30184133

Group type: EXPERIMENTAL
Intervention: Scopolamine (4 μg/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 29790614

Group type: EXPERIMENTAL
Intervention: Probiotic treatment (Lactobacillus rhamnosus and Enterococcus faecium)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (PG)
Number of subjects: 34
Study: 27044933

Group type: EXPERIMENTAL
Intervention: ADT + bevacizumab
Number of subjects: 102

Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 102
Study: 24183908

Group type: COMPARATOR
Intervention: Epidural catheter (Group A)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Paravertebral catheter (Group B)
Number of subjects: 52
Study: 24032706

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous heparin infusion (8 U/kg/hr progressing to 10 U/kg/hr over 36 hours) starting 12 hours after surgery until Day 14
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional subcutaneous heparin twice daily as deep vein thrombosis prophylaxis
Number of subjects: 86
Study: 20205099

Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT(4)) treatment for one year
Number of subjects: 21

Group type: COMPARATOR
Intervention: Iodine treatment only (Control)
Number of subjects: 21
Study: 18788565

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape obturator (TVT-O)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Both TVT and TVT-O
Number of subjects: 69
Study: 16490423

Group type: EXPERIMENTAL
Intervention: Primary coronary angioplasty
Number of subjects: 1450

Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 1450
Study: 14711190

Group type: EXPERIMENTAL
Intervention: 20 mg/day atorvastatin for 3 months
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 80 mg/day atorvastatin for 3 months
Number of subjects: 24
Study: 10781354

Group type: COMPARATOR
Intervention: Thrombolytic therapy in community hospitals (group A)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Thrombolytic therapy during transportation to angioplasty (group B)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Immediate transportation for primary angioplasty without pre-treatment with thrombolysis (group C)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Immediate transportation for primary angioplasty (group C)
Number of subjects: 300
Study: 8890313

Group type: EXPERIMENTAL
Intervention: Experimental task involving identification of left or right hand presented in different orientations; subjects mentally moved their arm to match the experimenter's arm position.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition with tactual stimulation without mental transformations.
Number of subjects: 0
Study: 2056455

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate rinsing (15 ml b.i.d.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tap water rinsing (15 ml b.i.d.)
Number of subjects: 30
Study: 6352046

Group type: EXPERIMENTAL
Intervention: Timed-release dihydroergotamine preparation 10 mg/per os/day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 30992295

Group type: EXPERIMENTAL
Intervention: 2-week antibiotic therapy
Number of subjects: 154

Group type: COMPARATOR
Intervention: 4-week antibiotic therapy
Number of subjects: 154
Study: 28976056

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 50
Study: 27270237

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg sc every 6 months
Number of subjects: 643

Group type: COMPARATOR
Intervention: Zoledronic Acid 5 mg iv once
Number of subjects: 643
Study: 24570297

Group type: EXPERIMENTAL
Intervention: Medication Monitoring and Optimization (MeMO) intervention, comprising continuous monitoring and tailored counseling sessions, N = 495
Number of subjects: 937

Group type: COMPARATOR
Intervention: Usual pharmacy care, N = 442
Number of subjects: 937
Study: 22050030

Group type: EXPERIMENTAL
Intervention: Methamphetamine (0, 12, 50 mg/70 kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: d-amphetamine (0, 12, 50 mg/70 kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Methamphetamine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Methamphetamine and d-amphetamine
Number of subjects: 13
Study: 21037194

Group type: EXPERIMENTAL
Intervention: At-home technique with 10% carbamide peroxide
Number of subjects: 17

Group type: COMPARATOR
Intervention: In-office technique with 38% hydrogen peroxide
Number of subjects: 17
Study: 17624482

Group type: EXPERIMENTAL
Intervention: Network-based rehabilitation intervention (3 in-patient periods totaling 21 days and a home visit by a professional)
Number of subjects: 741

Group type: COMPARATOR
Intervention: Standard social and health services (control group)
Number of subjects: 741
Study: 16316364

Group type: EXPERIMENTAL
Intervention: Non-iterative method without urea rebound measurement (BUN3)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Iterative method with BUN3
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Second generation formula of Daugirdas (when BUN3 is available)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Rate equation of Daugirdas and Schneditz (when BUN3 is not available)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Comparison of mKt/V and eKt/V
Number of subjects: 98
Study: 11958805

Group type: EXPERIMENTAL
Intervention: Alcohol (0.7 g/kg body mass) given 1 h after exercise
Number of subjects: 19

Group type: COMPARATOR
Intervention: Alcohol-free solution administered 1 h after exercise
Number of subjects: 19
Study: 16256705

Group type: EXPERIMENTAL
Intervention: R(+)‐ and S(‐)‐thioctic acid (TA) enantiomers administered orally and intravenously at a single dose of 200 mg rac‐TA.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: R(+)‐ and S(‐)‐thioctic acid (TA) enantiomers in patients with normal gastric emptying (group A, n=11).
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: R(+)‐ and S(‐)‐thioctic acid (TA) enantiomers in patients with delayed gastric emptying (group B, n=11).
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: R(+)‐ and S(‐)‐thioctic acid (TA) enantiomers in patients with delayed GET.
Number of subjects: 22
Study: 7714974

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (20 micrograms)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Sodium nitroprusside (300 micrograms)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Sodium nitroprusside (400 micrograms)
Number of subjects: 105
Study: 2495910

Group type: EXPERIMENTAL
Intervention: Intravenous rtPA (total dose, 100 mg over 3 h)
Number of subjects: 5011
Study: 699627

Group type: EXPERIMENTAL
Intervention: Diflunisal (500 mg) twice daily
Number of subjects: 51

Group type: COMPARATOR
Intervention: Dextropropoxyphene (65 mg) plus paracetamol (650 mg) 3-times daily
Number of subjects: 51
Study: 30992006

Group type: EXPERIMENTAL
Intervention: CPAP success
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Lamellar body count
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Gestational age
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Lamellar body count and gestational age interaction
Number of subjects: 125
Study: 28562271

Group type: EXPERIMENTAL
Intervention: Child care health consultation
Number of subjects: 2018

Group type: EXPERIMENTAL
Intervention: Years of director's experience
Number of subjects: 2018

Group type: EXPERIMENTAL
Intervention: Perceived barriers (e.g., lack of knowing what to do in the event of pandemic influenza)
Number of subjects: 2018

Group type: EXPERIMENTAL
Intervention: Concrete actions taken by directors to prepare their centers
Number of subjects: 2018

Group type: EXPERIMENTAL
Intervention: Experience as a center director during the 2009 influenza pandemic
Number of subjects: 2018
Study: 26999839

Group type: EXPERIMENTAL
Intervention: ABNS+SS (Allergen Blocking Nasal Spray + Seawater Spray)
Number of subjects: 60

Group type: COMPARATOR
Intervention: SS (Seawater Spray)
Number of subjects: 60
Study: 23501702

Group type: EXPERIMENTAL
Intervention: Sustained Attention to Response Task (SART; high Go low No‐Go)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional formatted vigilance task (TFT; high No‐Go low Go)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SART (random or fixed ordered)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TFT (random or fixed ordered)
Number of subjects: 0
Study: 21620927

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate (CHX) mouthwash (Periogard)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo mouthwash (control)
Number of subjects: 39
Study: 19568030

Group type: EXPERIMENTAL
Intervention: Unstable surface balance training (air-filled rubber disks, 5 weeks, thrice weekly sessions)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 19
Study: 16814397

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 14653285

Group type: EXPERIMENTAL
Intervention: Ultra‐Etch 35% phosphoric acid gel
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultra‐Etch AB 35% phosphoric acid gel with cetylpyridinium chloride antimicrobial agent
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultra‐Etch 35% phosphoric acid gel followed by Concepsis chlorhexidine gluconate antimicrobial solution
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultra‐Etch 35% phosphoric acid gel followed by Consepsis Scrub chlorhexidine gluconate antimicrobial slurry
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: No etchant and/or cavity pre‐treatment
Number of subjects: 60
Study: 11129093

Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg/day) administered from day 15 to day 18
Number of subjects: 13
Study: 8761192

Group type: EXPERIMENTAL
Intervention: Educational booklet on arthritis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational booklet plus instruction from a health professional
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no other intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 0
Study: 1565116

Group type: COMPARATOR
Intervention: Lateral tilting at various angles (0 degrees, 4 degrees, 8 degrees, 12 degrees, 16 degrees, and 20 degrees)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control position (0 degrees)
Number of subjects: 8
Study: 3890229

Group type: EXPERIMENTAL
Intervention: Lymecycline (300 mg bid for 7 days)
Number of subjects: 532

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: C. trachomatis presence
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Treatment effect
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: M. hominis presence, history of pelvic inflammatory disease, maternal age, gestational age, number of births, spontaneous and induced abortion, Hegar number
Number of subjects: 532
Study: 29729278

Group type: EXPERIMENTAL
Intervention: Hearing aids
Number of subjects: 0
Study: 26433040

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg orally 1 hour before general anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24789332

Group type: EXPERIMENTAL
Intervention: Multiple prenatal ultrasound scans and Doppler flow studies (intensive group)
Number of subjects: 1134

Group type: COMPARATOR
Intervention: Single ultrasound scan at 18 weeks' gestation (control group)
Number of subjects: 1134
Study: 22189527

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg daily)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 420
Study: 19482522

Group type: EXPERIMENTAL
Intervention: Suction drain
Number of subjects: 168

Group type: COMPARATOR
Intervention: Non-suction drain
Number of subjects: 168
Study: 18601757

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of ropivacaine (100 mL solution of ropivacaine in a concentration of 2 mg/mL) (Group A)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Combination of intravesical instillation and subepithelial injection of 2 mL (4 mg) at the site of biopsy (Group B)
Number of subjects: 52
Study: 15327933

Group type: EXPERIMENTAL
Intervention: Left temporal lobectomy (TL)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Right temporal lobectomy (TL)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Temporal lobectomy (TL) patients (both left and right)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 11470347

Group type: EXPERIMENTAL
Intervention: Quintuple buprenorphine dosing (5x daily maintenance dose)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sextuple buprenorphine dosing (6x daily maintenance dose)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 14
Study: 9347651

Group type: EXPERIMENTAL
Intervention: Standardized ginseng extract 150 mg per capsule, 2 capsules daily for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8289001

Group type: EXPERIMENTAL
Intervention: Concho-antropexy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Total inferior turbinectomy
Number of subjects: 25
Study: 3471610

Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30356423

Group type: EXPERIMENTAL
Intervention: Deep-layer acupoint PGLA embedding (DAPE)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Middle-layer acupoint PGLA embedding (MAPE)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sham acupoint embedding (SAE)
Number of subjects: 102
Study: 27884916

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 571

Group type: COMPARATOR
Intervention: Usual medical treatments (tranexamic/mefenamic acid, combined oestrogen-progestogen, or progesterone alone)
Number of subjects: 571